Dokumentenart: | Patent | ||||||
---|---|---|---|---|---|---|---|
Seitenanzahl: | 65 | ||||||
Datum: | 1986 | ||||||
Zusätzliche Informationen (Öffentlich): | CAN 106:138635 29-13 Organometallic and Organometalloidal Compounds Patent 19860828 1161-13-3P (N-Benzyloxycarbonyl-(L)-phenylalanine) Role: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent) (prepn. and amidation of); 29802-26-4P; 105469-00-9P; 105469-01-0P; 105469-02-1P; 105469-03-2P; 105469-04-3P; 105469-05-4P; 105469-06-5P; 105469-07-6P Role: SPN (Synthetic preparation), PREP (Preparation) (prepn. and complexation of, with platinum); 17430-32-9P; 29618-17-5P; 35373-92-3P; 104347-81-1P; 105469-08-7P; 105469-11-2P; 105500-30-9P Role: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent) (prepn. and redn. of); 105469-09-8P; 105469-10-1P Role: SPN (Synthetic preparation), PREP (Preparation) (prepn. of); 70-26-8DP; 70-47-3DP; 87-69-4DP; 320-77-4DP; 85612-60-8DP; 102050-52-2P; 104907-20-2DP; 105236-99-5P; 105237-00-1P; 105237-01-2P; 105237-02-3P; 105237-03-4P; 105237-04-5P; 105237-05-6P; 105237-06-7P; 105237-07-8P; 105237-08-9P; 105237-09-0P; 105237-10-3P; 105237-11-4P; 105237-12-5P; 105237-13-6P; 105237-16-9P; 105266-54-4P; 105308-31-4P; 105368-95-4P; 105855-89-8P; 105856-39-1P; 105856-40-4P; 105856-41-5P; 105856-44-8P; 105856-45-9P; 105856-46-0P; 105856-47-1P; 105856-48-2P; 105856-49-3P; 105856-50-6P; 105856-51-7P; 105856-52-8P; 105856-53-9P; 105856-54-0P; 105856-55-1P; 105856-56-2P; 105856-57-3P; 105856-58-4P; 105856-59-5P; 105856-60-8P; 105856-61-9P; 105856-63-1P; 105856-64-2P; 105856-65-3P; 105856-66-4P; 105870-24-4P; 105870-25-5P Role: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), SPN (Synthetic preparation), BIOL (Biological study), PREP (Preparation) (prepn. of, as antitumor agent); 7440-06-4DP Role: SPN (Synthetic preparation), PREP (Preparation) (prepn. of, as antitumor agents); 78684-05-6P; 105500-29-6P Role: SPN (Synthetic preparation), PREP (Preparation) (prepn., deprotection, and reaction of, with hydrobromic acid); 85612-60-8 Role: RCT (Reactant), RACT (Reactant or reagent) (reaction of, with Et chloroformate); 63-91-2 Role: RCT (Reactant), RACT (Reactant or reagent) (reaction of, with benzyl chloroformate); 2577-90-4 Role: RCT (Reactant), RACT (Reactant or reagent) (reaction of, with methylamine); 2627-86-3 ((S)-1-Phenylethylamine) Role: RCT (Reactant), RACT (Reactant or reagent) (reaction of, with protected phenylalanine); 5241-58-7 ((L)-Phenylalanineamide) Role: RCT (Reactant), RACT (Reactant or reagent) (reductive alkylation of) A1 DE 85-3506468 19850223 | ||||||
Institutionen: | Chemie und Pharmazie > Institut für Pharmazie > Entpflichtete oder im Ruhestand befindliche Professoren > Prof. Schönenberger | ||||||
Projekte: | SFB 234 | ||||||
Identifikationsnummer: |
| ||||||
Stichwörter / Keywords: | Neoplasm inhibitors (platinum benzylethylenediamine complexes as) platinum benzylethylenediamine prepn antitumor agent | ||||||
Dewey-Dezimal-Klassifikation: | 500 Naturwissenschaften und Mathematik > 540 Chemie | ||||||
Status: | Veröffentlicht | ||||||
Begutachtet: | Ja, diese Version wurde begutachtet | ||||||
An der Universität Regensburg entstanden: | Ja | ||||||
Dokumenten-ID: | 17656 |
Zusammenfassung
The title compds. I [R1-4 = H, C1-6 alkyl, PhCH2, phenylethyl; R5 = thienyl, indolyl, imidazolyl, (substituted) Ph; X = pharmaceutically acceptable anion], useful as antitumor agents, are prepd. by complexation of II by Pt compds. Thus, 1 mmol K2PtCl4 in H2O was treated with 1 mmol II (R1-4 = H, R5 = Ph) at 50 Deg and pH 6 in a flask protected from light to give I (R1-4 = H, R5 = Ph, X = Cl) ...
Zusammenfassung
The title compds. I [R1-4 = H, C1-6 alkyl, PhCH2, phenylethyl; R5 = thienyl, indolyl, imidazolyl, (substituted) Ph; X = pharmaceutically acceptable anion], useful as antitumor agents, are prepd. by complexation of II by Pt compds. Thus, 1 mmol K2PtCl4 in H2O was treated with 1 mmol II (R1-4 = H, R5 = Ph) at 50 Deg and pH 6 in a flask protected from light to give I (R1-4 = H, R5 = Ph, X = Cl) (III). I were effective against P 388 leukemia, e.g. at 100-200 mg/kg orally in mice. Tablets (100 mg) were formulated from lactose 300, corn starch 130, Mg stearate 10, and III 200 g.
Metadaten zuletzt geändert: 24 Mai 2018 12:18